Voyager Therapeutics to Present Broad Set of Translational D

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set

Related Keywords

Michael Grannan , Damien Maura , Varshini Venkatesan , Todd Carter , Adam Bero , Shiron Lee , Hechen Bao , Roberto Facendola , Brett Hoffman , Matteo Placidi , Tyler Moyer , Trista Morrison , Daniel Cox , Brooke Shenkin , Hamza Khalid , Kishan Shah , Principal Research , Nasdaq , Neurocrine Biosciences Inc , Sangamo Therapeutics Inc , American Society Of Gene Cell Therapy , Senior Research Associate , Analytical Sciences , Research Associate , Voyager Therapeutics Inc , Exchange Commission , American Society , Cell Therapy , Chief Scientific Officer , Novel Capsid , Associate Director , Senior Scientist , Matthew Child , Principal Research Associate , Downstream Process , Senior Associate Engineer , Capsid Discovery , Tropism Redirection , Cell Type Specific Expression , Astrazeneca Rare Disease , Novartis Pharma , Neurocrine Biosciences , Sangamo Therapeutics , Voyager Therapeutics , Private Securities Litigation Reform Act , Annual Report ,